NTPX-07 - Ph II Licensing Opportunity
Novel Oral Platinum Complex for revention of secondaries in Head and Neck Cancer and other Solid Tumors.
Introduction
Onset of multiple therapies like Surgery, Radiation, Cytotoxic Agents, MAbs, etc. have enabled health professionals an arsenal to deal primary cancer with relatively higher success rates for at least early diagnosed patients, but the scenario is vastly different for the secondary cancer or metastasized cancer cases.
Metastasis
The primary cause of cancer-related deaths, even in tumors that are responsive to radiotherapy or chemotherapy, is often the main reason for treatment failure.
Metastatic tumors not only are difficult to treat with conventional surgery or radiotherapy due to their anatomically diffused localization in different organs, but also, in most cases, they are resistant to cytotoxic agents. The mechanisms underlying cancer metastasis are extremely complicated and involve multiple cell types and several key signaling pathways. The patients are helpless in the window period post treatment of primary tumors till the date they are diagnosed with deadly Secondary cancer as there are no current therapies addressing this period.
NTPX-07
NTPX-07 is precisely positioned to be administered to patients after the primary cancer treatment is completed with the help of multiple immunomodulatory pathways strengthening the body’s healthy cells as well as immune system.
Chemotherapy
Disadvantages
- Immunosuppression and Myelosuppression
- Neutropenic Enterocolitis
- Gastrointestinal Distress
- Anemia
- Fatigue
- Nausea and Vomiting
- Hair Loss
- Secondary Neoplasm
- Infertility
- Peripheral Neuropathy
Limitations
- Does not always work
- It may not completely destroy cancer
- Cannot cross blood brain barrier
- Drug Resistance is major cause of concern
Our Key Findings from the Study
- We have in-house synthesized NTPX-07 by green nanotechnology; due to its very small size (137.5 nm), it quickly enters into the cells
-
NTPX-07 was well tolerated up to the high concentration of dose in patients and was considered safe
- NTPX-07 also showed potential to stabilize the disease in around 67% of study participants who have advanced metastatic tumours resistant to available chemotherapeutic options
We believe in Patient centric approach instead of tumor centric approach
The efforts in this direction led us to become First Company to bring Platinum as Anticancer Compound.
Why Platinum ?
Platinum chemistry plays a dominant role in the drugs for Oncology. Even though the base chemistry is of platinum, many platinum based drugs like Cisplatin, Carboplatin, Oxaliplatin, etc. have a different therapeutic segment for which it is a preferred treatment alternative although with a severe limitation of dose related toxicity because of their inherent cytotoxic nature.
RBPL successfully removed the dose related toxicity for platinum with a unique patented “Green technology.
Key Features
- NTPX-07 is an oral platinum based anti-cancer compound indicated for management of various solid malignant tumors
- Administered orally in an outpatient setting resulting in major cost saving for patients
- This compound has shown excellent safety and tolerability profile in initial preclinical studies. Less requirement of supportive therapy and patient care because of improved Quality of Life
Preclinical Profile
- Positive activity for Prostate, Lung, Ovary and Pancreas tumor cell lines
- No adverse effect on normal cell lines
- No adverse toxicity effects demonstrated with rodent and non-rodent Toxicity studies
- In vivo studies demonstrate potential for prevention of Cancer recurrence
Unique Value Proposition
- First Orally Administered Platinum based drug
- Targeting unmet need: For prevention of Cancer recurrence
- Best tolerated as compared to any other anti-cancer drug
- No special handling requirements for drug in the supply chain
- There is no competitor drug in its class
- NTPX-07 has potential to cater 30% substantial global cancer market including prophylactic and chemo-preventive areas.
Potential Segmentation
- Head and Neck Cancers
- Pancreatic Cancer
- In Metronomic scheduling
- As a Radio-sensitizer
Patents / Certifications
- Granted & enforceable patent in EU region
- Granted & enforceable US patent
- At final stage of grant at Indian Patent Office
Status of Development
- The company successfully completed Phase-I Clinical trial on patients with solid tumors refractory to conventional therapies & advanced metastatic tumors.
- Currently, under process of Ph II/III submission to DCGI for Head and Neck Cancers